You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCyclothiazide
Accession NumberDB00606  (APRD00895, EXPT01082)
TypeSmall Molecule
GroupsApproved
DescriptionAs a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like cyclothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of cyclothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle. Cyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Structure
Thumb
Synonyms
6-chloro-3-(2-Norbornen-5-yl)-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
6-chloro-3,4-dihydro-3-(2-Norbornen-5-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
6-chloro-3,4-dihydro-3-(2-Norbornen-5-yl)-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide
6-chloro-3,4-dihydro-3-(5-Norbornen-2-yl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
Ciclotiazida
Ciclotiazide
Cyclothiazide
Cyclothiazidum
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcquirelNot Available
AnhydronLilly
DoburilBoehringer Ingelheim
FluidilNot Available
RenazideNot Available
TensodiuralNot Available
ValmiranBoehringer Ingelheim
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIP71U09G5BW
CAS number2259-96-3
WeightAverage: 389.878
Monoisotopic: 389.027075102
Chemical FormulaC14H16ClN3O4S2
InChI KeyInChIKey=BOCUKUHCLICSIY-UHFFFAOYSA-N
InChI
InChI=1S/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)
IUPAC Name
3-{bicyclo[2.2.1]hept-5-en-2-yl}-6-chloro-1,1-dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC(NS(=O)(=O)C2=C1)C1CC2CC1C=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Secondary aliphatic/aromatic amine
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationCyclothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
PharmacodynamicsLike other thiazides, cyclothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Cyclothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Cyclothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate.
Mechanism of actionHydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.Hydrochlorothiazide, a thiazide diuretic, inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, hydrochlorothiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityOral LD50 in mouse is > 10000 mg/kg, and > 4000 mg/kg in rat. Signs of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Cyclothiazide Action PathwayDrug actionSMP00103
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9936
Blood Brain Barrier-0.8102
Caco-2 permeable-0.7087
P-glycoprotein substrateNon-substrate0.6003
P-glycoprotein inhibitor INon-inhibitor0.8315
P-glycoprotein inhibitor IINon-inhibitor0.9504
Renal organic cation transporterNon-inhibitor0.894
CYP450 2C9 substrateNon-substrate0.6644
CYP450 2D6 substrateNon-substrate0.8212
CYP450 3A4 substrateNon-substrate0.6385
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.7478
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.8015
CarcinogenicityNon-carcinogens0.813
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9232 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9813
hERG inhibition (predictor II)Non-inhibitor0.8693
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
  • Pharmacia and upjohn co
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point229-230Muller, E. and Hasspacher, K.; US. Patent 3,275,625; September 27,1966; assigned to Boehringer lngelheim GmbH, Germany.
logP1.95YAMAZAKI,M ET AL. (1984)
Predicted Properties
PropertyValueSource
Water Solubility0.279 mg/mLALOGPS
logP1.32ALOGPS
logP0.94ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)9.06ChemAxon
pKa (Strongest Basic)-2.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity92.65 m3·mol-1ChemAxon
Polarizability37.1 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.61 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Muller, E. and Hasspacher, K.; US. Patent 3,275,625; September 27,1966; assigned to
Boehringer lngelheim GmbH, Germany.

General ReferencesNot Available
External Links
ATC CodesC03AA09C03AB09
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSDownload (74.8 KB)
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Cyclothiazide.
AcebutololCyclothiazide may increase the hypotensive activities of Acebutolol.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclothiazide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Cyclothiazide.
AliskirenCyclothiazide may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Cyclothiazide.
AlprenololCyclothiazide may increase the hypotensive activities of Alprenolol.
AmbrisentanCyclothiazide may increase the hypotensive activities of Ambrisentan.
AmifostineCyclothiazide may increase the hypotensive activities of Amifostine.
AmlodipineAmlodipine may increase the hypotensive activities of Cyclothiazide.
AtenololAtenolol may increase the hypotensive activities of Cyclothiazide.
BenazeprilBenazepril may increase the hypotensive activities of Cyclothiazide.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Cyclothiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Cyclothiazide.
BepridilCyclothiazide may increase the hypotensive activities of Bepridil.
BetaxololBetaxolol may increase the hypotensive activities of Cyclothiazide.
BethanidineBethanidine may increase the hypotensive activities of Cyclothiazide.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Cyclothiazide.
BimatoprostCyclothiazide may increase the hypotensive activities of Bimatoprost.
BisoprololCyclothiazide may increase the hypotensive activities of Bisoprolol.
BosentanBosentan may increase the hypotensive activities of Cyclothiazide.
BretyliumCyclothiazide may increase the hypotensive activities of Bretylium.
BrimonidineCyclothiazide may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Cyclothiazide.
BupranololCyclothiazide may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclothiazide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclothiazide.
CandesartanCyclothiazide may increase the hypotensive activities of Candesartan.
CandoxatrilCyclothiazide may increase the hypotensive activities of Candoxatril.
CaptoprilCyclothiazide may increase the hypotensive activities of Captopril.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Cyclothiazide.
CaroxazoneCaroxazone may increase the hypotensive activities of Cyclothiazide.
CarteololCarteolol may increase the hypotensive activities of Cyclothiazide.
CarvedilolCyclothiazide may increase the hypotensive activities of Carvedilol.
CeliprololCyclothiazide may increase the hypotensive activities of Celiprolol.
ChlorothiazideCyclothiazide may increase the hypotensive activities of Chlorothiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Cyclothiazide.
CilazaprilCyclothiazide may increase the hypotensive activities of Cilazapril.
ClonidineClonidine may increase the hypotensive activities of Cyclothiazide.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclothiazide.
CryptenamineCyclothiazide may increase the hypotensive activities of Cryptenamine.
DebrisoquinCyclothiazide may increase the hypotensive activities of Debrisoquin.
DeserpidineCyclothiazide may increase the hypotensive activities of Deserpidine.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Cyclothiazide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Cyclothiazide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Cyclothiazide.
DiazoxideDiazoxide may increase the hypotensive activities of Cyclothiazide.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Cyclothiazide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Cyclothiazide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Cyclothiazide.
DiltiazemDiltiazem may increase the hypotensive activities of Cyclothiazide.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Cyclothiazide.
DorzolamideCyclothiazide may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Cyclothiazide.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Cyclothiazide.
EfonidipineCyclothiazide may increase the hypotensive activities of Efonidipine.
EnalaprilEnalapril may increase the hypotensive activities of Cyclothiazide.
EnalaprilatCyclothiazide may increase the hypotensive activities of Enalaprilat.
EpoprostenolCyclothiazide may increase the hypotensive activities of Epoprostenol.
EprosartanCyclothiazide may increase the hypotensive activities of Eprosartan.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Cyclothiazide.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Cyclothiazide.
FelodipineCyclothiazide may increase the hypotensive activities of Felodipine.
FenoldopamCyclothiazide may increase the hypotensive activities of Fenoldopam.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclothiazide.
FosinoprilFosinopril may increase the hypotensive activities of Cyclothiazide.
FurazolidoneFurazolidone may increase the hypotensive activities of Cyclothiazide.
GuanabenzCyclothiazide may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Cyclothiazide.
GuanethidineCyclothiazide may increase the hypotensive activities of Guanethidine.
GuanfacineCyclothiazide may increase the hypotensive activities of Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Cyclothiazide.
HexamethoniumCyclothiazide may increase the hypotensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypotensive activities of Cyclothiazide.
HydralazineCyclothiazide may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideCyclothiazide may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Cyclothiazide.
HydroflumethiazideCyclothiazide may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclothiazide.
IloprostIloprost may increase the hypotensive activities of Cyclothiazide.
IndapamideCyclothiazide may increase the hypotensive activities of Indapamide.
IndenololCyclothiazide may increase the hypotensive activities of Indenolol.
IndoraminCyclothiazide may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Cyclothiazide.
IproniazidIproniazid may increase the hypotensive activities of Cyclothiazide.
IrbesartanCyclothiazide may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Cyclothiazide.
IsradipineIsradipine may increase the hypotensive activities of Cyclothiazide.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Cyclothiazide.
LabetalolLabetalol may increase the hypotensive activities of Cyclothiazide.
LacidipineCyclothiazide may increase the hypotensive activities of Lacidipine.
LatanoprostCyclothiazide may increase the hypotensive activities of Latanoprost.
LercanidipineLercanidipine may increase the hypotensive activities of Cyclothiazide.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Cyclothiazide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclothiazide.
LisinoprilCyclothiazide may increase the hypotensive activities of Lisinopril.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Cyclothiazide.
LofexidineCyclothiazide may increase the hypotensive activities of Lofexidine.
LosartanCyclothiazide may increase the hypotensive activities of Losartan.
MacitentanCyclothiazide may increase the hypotensive activities of Macitentan.
ManidipineCyclothiazide may increase the hypotensive activities of Manidipine.
MebanazineMebanazine may increase the hypotensive activities of Cyclothiazide.
MecamylamineCyclothiazide may increase the hypotensive activities of Mecamylamine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclothiazide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Cyclothiazide.
MethyldopaCyclothiazide may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Cyclothiazide.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cyclothiazide.
MetipranololCyclothiazide may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Cyclothiazide.
MetoprololMetoprolol may increase the hypotensive activities of Cyclothiazide.
MibefradilCyclothiazide may increase the hypotensive activities of Mibefradil.
MinaprineMinaprine may increase the hypotensive activities of Cyclothiazide.
MinoxidilMinoxidil may increase the hypotensive activities of Cyclothiazide.
MoclobemideMoclobemide may increase the hypotensive activities of Cyclothiazide.
MoexiprilCyclothiazide may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Cyclothiazide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclothiazide.
MoxonidineCyclothiazide may increase the hypotensive activities of Moxonidine.
NadololCyclothiazide may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclothiazide.
NebivololCyclothiazide may increase the hypotensive activities of Nebivolol.
NialamideNialamide may increase the hypotensive activities of Cyclothiazide.
NicardipineCyclothiazide may increase the hypotensive activities of Nicardipine.
NicorandilCyclothiazide may increase the hypotensive activities of Nicorandil.
NiguldipineCyclothiazide may increase the hypotensive activities of Niguldipine.
NilvadipineCyclothiazide may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Cyclothiazide.
NisoldipineNisoldipine may increase the hypotensive activities of Cyclothiazide.
NitrendipineCyclothiazide may increase the hypotensive activities of Nitrendipine.
NitroprussideNitroprusside may increase the hypotensive activities of Cyclothiazide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Cyclothiazide.
ObinutuzumabCyclothiazide may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Cyclothiazide.
OlmesartanOlmesartan may increase the hypotensive activities of Cyclothiazide.
OmapatrilatCyclothiazide may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Cyclothiazide.
OxprenololCyclothiazide may increase the hypotensive activities of Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclothiazide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Cyclothiazide.
PargylineCyclothiazide may increase the hypotensive activities of Pargyline.
PenbutololCyclothiazide may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclothiazide.
PentoliniumCyclothiazide may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cyclothiazide.
PerindoprilCyclothiazide may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclothiazide.
PhenelzinePhenelzine may increase the hypotensive activities of Cyclothiazide.
PheniprazinePheniprazine may increase the hypotensive activities of Cyclothiazide.
PhenoxybenzamineCyclothiazide may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Cyclothiazide.
PhentolamineCyclothiazide may increase the hypotensive activities of Phentolamine.
PinacidilCyclothiazide may increase the hypotensive activities of Pinacidil.
PindololCyclothiazide may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Cyclothiazide.
PivhydrazinePivhydrazine may increase the hypotensive activities of Cyclothiazide.
PolythiazideCyclothiazide may increase the hypotensive activities of Polythiazide.
PrazosinPrazosin may increase the hypotensive activities of Cyclothiazide.
PropranololPropranolol may increase the hypotensive activities of Cyclothiazide.
QuinaprilCyclothiazide may increase the hypotensive activities of Quinapril.
QuinineQuinine may increase the hypotensive activities of Cyclothiazide.
RamiprilRamipril may increase the hypotensive activities of Cyclothiazide.
RasagilineRasagiline may increase the hypotensive activities of Cyclothiazide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclothiazide.
RemikirenRemikiren may increase the hypotensive activities of Cyclothiazide.
RescinnamineCyclothiazide may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Cyclothiazide.
RiociguatCyclothiazide may increase the hypotensive activities of Riociguat.
RituximabCyclothiazide may increase the hypotensive activities of Rituximab.
SafrazineSafrazine may increase the hypotensive activities of Cyclothiazide.
SaprisartanCyclothiazide may increase the hypotensive activities of Saprisartan.
SelegilineSelegiline may increase the hypotensive activities of Cyclothiazide.
SelexipagCyclothiazide may increase the hypotensive activities of Selexipag.
SildenafilSildenafil may increase the antihypertensive activities of Cyclothiazide.
SitaxentanCyclothiazide may increase the hypotensive activities of Sitaxentan.
SpiraprilCyclothiazide may increase the hypotensive activities of Spirapril.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclothiazide.
TadalafilTadalafil may increase the antihypertensive activities of Cyclothiazide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Cyclothiazide.
TelmisartanCyclothiazide may increase the hypotensive activities of Telmisartan.
TemocaprilCyclothiazide may increase the hypotensive activities of Temocapril.
TerlipressinCyclothiazide may increase the hypotensive activities of Terlipressin.
TiboloneCyclothiazide may increase the hypotensive activities of Tibolone.
TicrynafenCyclothiazide may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Cyclothiazide.
TolazolineCyclothiazide may increase the hypotensive activities of Tolazoline.
ToloxatoneToloxatone may increase the hypotensive activities of Cyclothiazide.
TorasemideTorasemide may increase the hypotensive activities of Cyclothiazide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Cyclothiazide.
TrandolaprilTrandolapril may increase the hypotensive activities of Cyclothiazide.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Cyclothiazide.
TranylcypromineTranylcypromine may increase the hypotensive activities of Cyclothiazide.
TravoprostTravoprost may increase the hypotensive activities of Cyclothiazide.
TreprostinilTreprostinil may increase the hypotensive activities of Cyclothiazide.
TrichlormethiazideCyclothiazide may increase the hypotensive activities of Trichlormethiazide.
TrimazosinCyclothiazide may increase the hypotensive activities of Trimazosin.
TrimethaphanCyclothiazide may increase the hypotensive activities of Trimethaphan.
UdenafilUdenafil may increase the antihypertensive activities of Cyclothiazide.
UnoprostoneCyclothiazide may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Cyclothiazide.
VardenafilVardenafil may increase the antihypertensive activities of Cyclothiazide.
XylometazolineCyclothiazide may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Cyclothiazide.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
May be involved in forming the receptor site for cardiac glycoside binding or may modulate the transport function of the sodium ATPase.
Gene Name:
FXYD2
Uniprot ID:
P54710
Molecular Weight:
7283.265 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Rammes G, Zeilhofer HU, Collingridge GL, Parsons CG, Swandulla D: Expression of early hippocampal CA1 LTP does not lead to changes in AMPA-EPSC kinetics or sensitivity to cyclothiazide. Pflugers Arch. 1999 Jan;437(2):191-6. [PubMed:9929558 ]
  2. Rammes G, Swandulla D, Collingridge GL, Hartmann S, Parsons CG: Interactions of 2,3-benzodiazepines and cyclothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. Br J Pharmacol. 1996 Mar;117(6):1209-21. [PubMed:8882618 ]
  3. Fleck MW, Bahring R, Patneau DK, Mayer ML: AMPA receptor heterogeneity in rat hippocampal neurons revealed by differential sensitivity to cyclothiazide. J Neurophysiol. 1996 Jun;75(6):2322-33. [PubMed:8793745 ]
  4. Pirotte B, Podona T, Diouf O, de Tullio P, Lebrun P, Dupont L, Somers F, Delarge J, Morain P, Lestage P, Lepagnol J, Spedding M: 4H-1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4H-1,2, 4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R/S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors: design, synthesis, pharmacology, and structure-activity relationships. J Med Chem. 1998 Jul 30;41(16):2946-59. [PubMed:9685234 ]
  5. Larson J, Le TT, Hall RA, Lynch G: Effects of cyclothiazide on synaptic responses in slices of adult and neonatal rat hippocampus. Neuroreport. 1994 Jan 12;5(4):389-92. [PubMed:8003661 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Liljequist S, Cebers G, Kalda A: Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons. Biochem Pharmacol. 1995 Nov 27;50(11):1761-74. [PubMed:8615854 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23